Bromodomain-containing protein 4 (BRD4)
BRD4 (bromodomain-containing protein 4) is a member of the BET (bromodomain and extra-terminal domain) family of epigenetic reader proteins.
BRD4 (bromodomain-containing protein 4) is a member of the BET (bromodomain and extra-terminal domain) family of epigenetic reader proteins. It recognizes acetylated lysine residues on histones through its bromodomains and helps regulate chromatin-associated transcription, including RNA polymerase II–mediated gene expression. Because of this role, BRD4 is widely studied as a regulator of cell growth, survival, and oncogenic transcriptional programs.
In biomedical research, BRD4 is an important therapeutic target in cancer and other disease contexts where transcriptional control is dysregulated. Inhibition or degradation of BRD4 can suppress expression of tumor-driving genes, alter signaling pathways such as NF-κB signaling and Wnt/β-catenin pathway-related programs, and affect processes including proliferation, ferroptosis sensitivity, and viral latency-associated protein expression.
Where the papers sit
21 papers from the last 6 months study Bromodomain-containing protein 4 (BRD4) directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 2 human data · 15 preclinical · 4 unclassified
Themes one subject · 1 paradigm shift
Those 21 are all about one subject.
-
BRD4 Drug Development
BRD4 drug development is expanding from small-molecule inhibition toward PROTAC and nano-PROTAC degradation, including strategies that overcome CRBN or VHL deficiency and control activity in space and time. Anticancer applications dominate, spanning acute myeloid and megakaryoblastic leukemia, pancreatic, triple-negative breast, and other tumors. Combination approaches pair BRD4 targeting with PARP or HDAC inhibition, radiotherapy, oncolytic viruses, or PD-L1-directed immunotherapy, with c-JUN/CCL2 and PIM1 emerging as mechanistic vulnerabilities. Non-oncology work extends BRD4 modulation to corneal injury and idiopathic pulmonary fibrosis, but clinical translation remains open.
BRD4 degradation need not depend on conventional CRBN- or VHL-recruiting PROTACs
The GID4-recruiting BRD4 degrader study and the RIPK1-mediated RIMTAC study assumed the usual PROTAC architecture was constrained by reliance on CRBN or direct VHL recruitment; instead, the GID4 ligand a11 degraded BRD4 in CRBN- and VHL-deficient models, while RIMTAC recruited VHL indirectly through a RIPK1–VHL complex to degrade BRD4. Together, they replace dependence on the conventional recruitment routes with viable alternative mechanisms that can overcome E3-ligase deficiencies and broaden the design space for BRD4 degraders 42402035Jul 42417401Jul.
Papers
The 21 papers from the last 6 months that study Bromodomain-containing protein 4 (BRD4) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
BRD4 Drug Development (21)
- Design and Biological Evaluation of a Potent Dual PARP and BRD4 Inhibitor for Tumor Therapy via Disrupting HRR and BRD4-cJUN-CCL2 Axis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018612
- Development of a photocaged CLIPTAC for spatiotemporal control of protein degradation. Bioorganic chemistry · 25 Oct 2026 PMID 42927673
- Discovery of a novel BRD4 inhibitor for the treatment of acute myeloid leukemia. Bioorganic chemistry · 10 Oct 2026 PMID 42858492
- In Situ Bioorthogonal Synthesis of PROTACs via Dual-Responsive Cleavage for Synergistic Photo-Immunotherapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 27 Sept 2026 PMID 42801629
- BRD4 inhibition mitigates acute and chronic corneal injury following topical nitrogen mustard exposure. Molecular therapy : the journal of the American Society of Gene Therapy · 3 Sept 2026 PMID 42687381
- Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy. ACS nano · 18 Aug 2026 PMID 42611240
- Sequential Disruption of Tumor Camouflage and Metabolic Coercion by Cascade-Acting Nano-Proteolysis Targeting Chimera Engines to Reprogram the Immune Ecosystem. ACS nano · 11 Aug 2026 PMID 42579417
- An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer. Cell reports. Medicine · 29 Jul 2026 PMID 42526440
- PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy. Materials today. Bio · 12 Jul 2026 PMID 42436803
- RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1. Journal of medicinal chemistry · 8 Jul 2026 PMID 42417401
- GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency. Journal of medicinal chemistry · 5 Jul 2026 PMID 42402035
- Identification of 3-arylquinoxalin-2(1H)-one derivatives targeting BRD4 BD1 as efficient anticancer agents. European journal of medicinal chemistry · 3 Jul 2026 PMID 42398403
- HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery. Proceedings of the National Academy of Sciences of the United States of America · 25 Jun 2026 PMID 42348617
- Inhalable Polymeric PROTAC Nanococktail for Targeted Protein Degradation in Idiopathic Pulmonary Fibrosis. Journal of the American Chemical Society · 24 Jun 2026 PMID 42341263
- BRD4 regulation of PIM1 identifies a novel therapeutic vulnerability in acute megakaryoblastic leukemia. Cancer cell international · 18 Jun 2026 PMID 42310709
- PyMolGen: Database-Driven Molecular Generation of Drug-Like Compounds. Journal of chemical information and modeling · 16 Jun 2026 PMID 42298369
- Design, synthesis and biological evaluation of novel CDK8/BRD4 dual inhibitors. Bioorganic & medicinal chemistry letters · 12 Jun 2026 PMID 42285310
- Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. Angewandte Chemie (International ed. in English) · 12 Jun 2026 PMID 42283322
- Targeting BRD2 and BRD4 inhibit the growth of KSHV-infected immortalized endothelial cells through suppression of LANA translation. PLoS pathogens · 1 Jun 2026 PMID 42224297
- Stress granule assembly represents a therapeutic vulnerability in super-enhancer-driven circMLB-mediated glioblastoma temozolomide resistance. Cancer letters · 21 May 2026 PMID 42167397
- Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors. European journal of medicinal chemistry · 21 May 2026 PMID 42166816
By study type
Human data, design not indexed (2)
- Development of a photocaged CLIPTAC for spatiotemporal control of protein degradation. Bioorganic chemistry · 25 Oct 2026 PMID 42927673
- Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. Angewandte Chemie (International ed. in English) · 12 Jun 2026 PMID 42283322
Preclinical: animal, cell and lab studies (15)
- Design and Biological Evaluation of a Potent Dual PARP and BRD4 Inhibitor for Tumor Therapy via Disrupting HRR and BRD4-cJUN-CCL2 Axis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018612
- Discovery of a novel BRD4 inhibitor for the treatment of acute myeloid leukemia. Bioorganic chemistry · 10 Oct 2026 PMID 42858492
- BRD4 inhibition mitigates acute and chronic corneal injury following topical nitrogen mustard exposure. Molecular therapy : the journal of the American Society of Gene Therapy · 3 Sept 2026 PMID 42687381
- Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy. ACS nano · 18 Aug 2026 PMID 42611240
- Sequential Disruption of Tumor Camouflage and Metabolic Coercion by Cascade-Acting Nano-Proteolysis Targeting Chimera Engines to Reprogram the Immune Ecosystem. ACS nano · 11 Aug 2026 PMID 42579417
- An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer. Cell reports. Medicine · 29 Jul 2026 PMID 42526440
- GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency. Journal of medicinal chemistry · 5 Jul 2026 PMID 42402035
- Identification of 3-arylquinoxalin-2(1H)-one derivatives targeting BRD4 BD1 as efficient anticancer agents. European journal of medicinal chemistry · 3 Jul 2026 PMID 42398403
- HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery. Proceedings of the National Academy of Sciences of the United States of America · 25 Jun 2026 PMID 42348617
- Inhalable Polymeric PROTAC Nanococktail for Targeted Protein Degradation in Idiopathic Pulmonary Fibrosis. Journal of the American Chemical Society · 24 Jun 2026 PMID 42341263
- PyMolGen: Database-Driven Molecular Generation of Drug-Like Compounds. Journal of chemical information and modeling · 16 Jun 2026 PMID 42298369
- Design, synthesis and biological evaluation of novel CDK8/BRD4 dual inhibitors. Bioorganic & medicinal chemistry letters · 12 Jun 2026 PMID 42285310
- Targeting BRD2 and BRD4 inhibit the growth of KSHV-infected immortalized endothelial cells through suppression of LANA translation. PLoS pathogens · 1 Jun 2026 PMID 42224297
- Stress granule assembly represents a therapeutic vulnerability in super-enhancer-driven circMLB-mediated glioblastoma temozolomide resistance. Cancer letters · 21 May 2026 PMID 42167397
- Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors. European journal of medicinal chemistry · 21 May 2026 PMID 42166816
Unclassified: not yet indexed with MeSH (4)
- In Situ Bioorthogonal Synthesis of PROTACs via Dual-Responsive Cleavage for Synergistic Photo-Immunotherapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 27 Sept 2026 PMID 42801629
- PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy. Materials today. Bio · 12 Jul 2026 PMID 42436803
- RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1. Journal of medicinal chemistry · 8 Jul 2026 PMID 42417401
- BRD4 regulation of PIM1 identifies a novel therapeutic vulnerability in acute megakaryoblastic leukemia. Cancer cell international · 18 Jun 2026 PMID 42310709
Written from 21 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.